金龙胶囊联合肝动脉化疗栓塞治疗原发性肝癌疗效观察  

Clinical studies of the combination therapy with Jinlong capsule and chemical therapy and embolization by hepatic artery catheterization on primary hepatic carcinoma

作　　者：张才擎[1] 梁铁军[1] 袁孟彪[1] 

机构地区：[1]山东省立医院内科,济南250021

出　　处：《北京医学》2005年第6期357-359,共3页Beijing Medical Journal

摘　　要：目的探讨金龙胶囊对原发性肝癌的治疗作用。方法224例不能手术的原发性肝癌患者随机分为金龙胶囊联合肝动脉化疗栓塞组(治疗组)116例及单纯肝动脉化疗栓塞组(对照组)108例,观察治疗后6个月、1年、2年、3年疗效,生存率和生活质量。结果治疗组治疗后1年、2年、3年有效率分别为60.0%、58.2%、56.5%,对照组分别为42.3%、35.1%、18.2%,治疗组明显优于对照组(P<0.05);治疗组治疗后1年、2年、3年生存率分别为77.6%、47.4%、19.8%,对照组为64.8%、34.3%、10.2%,治疗组明显优于对照组(P<0.05);治疗组各项生活质量评分明显优于对照组(P<0.05)。结论金龙胶囊可显著提高原发性肝癌患者的化疗效果、生存时间和生活质量,是治疗原发性肝癌的有效药物。Objective To study the clinical effect of Jinlong capsule on primary hepatic carcinoma (PHC). Methods 224 cases with PHC, that could not be treated by operaton were classified randomly into two groups: combination therapy group (treatment group, 116 cases) and chemical therapy and embolization by hepatic artery catheterization group (control group, 108 cases). The effects, survival rate and guality of life were evaluated at 6 months, 1 year, 2 years and 3 years after treatment respectively. Results The effective rate, survival rate and guality of life of treatment group were significantly better than those of the control group (P<0.05) 1 year, 2 years and 3 years and after treatment. Conclusions Jinlong capsule can significantly improve the effect of chemical therapy sarvival period and quality of life of patients with PHC. It is an effective drug in the treatment of PHC.

关 键 词：肝动脉化疗栓塞治疗 金龙胶囊 疗效观察 原发性肝癌患者 生活质量评分 治疗组 对照组 3年生存率 治疗后 治疗作用 化疗效果 生存时间 有效药物 有效率 

分 类 号：R735.7[医药卫生—肿瘤] R737.33[医药卫生—临床医学]